MedTrace Logo

The Safety and Effectiveness of Didanosine Plus Stavudine Plus Delavirdine Mesylate Plus MKC-442 in HIV-Infected Patients Who Have Not Had Success With Protease Inhibitors

NCT00002420 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2008-08-14

No results posted yet for this study

Summary

The purpose of this study is to see if it is safe and effective to give MKC-442, didanosine (ddI), stavudine (d4T), and delavirdine (DLV) to HIV-positive patients.

Conditions

  • HIV Infections

Interventions

DRUG

Emivirine

DRUG

Hydroxyurea

DRUG

Delavirdine mesylate

DRUG

Stavudine

DRUG

Didanosine

Sponsors & Collaborators

  • Pharmacia and Upjohn

    collaborator INDUSTRY

  • Triangle Pharmaceuticals

    collaborator INDUSTRY

  • Bristol-Myers Squibb

    lead INDUSTRY

Study Design

Purpose
TREATMENT
Masking
NONE

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00002420 on ClinicalTrials.gov